Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001 Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...

Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001 THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...